Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
33.33
-1.81 (-5.15%)
NASDAQ · Last Trade: Jun 12th, 6:58 PM EDT
Detailed Quote
Previous Close
35.14
Open
35.22
Bid
33.00
Ask
35.20
Day's Range
32.79 - 35.37
52 Week Range
26.47 - 41.61
Volume
1,095,623
Market Cap
1.90B
PE Ratio (TTM)
12.72
EPS (TTM)
2.6
Dividend & Yield
N/A (N/A)
1 Month Average Volume
631,340
Chart
About Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with neurological disorders. The company is dedicated to addressing unmet medical needs in this space, particularly in the areas of rare and complex conditions. By leveraging proprietary research and development capabilities, Harmony Biosciences aims to bring forth therapies that improve the quality of life for patients, while also advancing scientific understanding of neurological diseases. Their portfolio includes products targeting specific disorders, reflecting a commitment to enhancing patient outcomes through personalized and effective treatments. Read More
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of preclinical pharmacological effect data for BP1.15205, an investigational, highly potent, and potentially best-in-class orexin 2 receptor (OX2R) agonist, which demonstrated significant wake-promoting and cataplexy-suppressing effects in a standard transgenic mouse model of narcolepsy type 1. The data will be presented at the 39th Annual Meeting of the Associated Professional Sleep Societies (APSS) “SLEEP” on Wednesday, June 11, 2025, at 10:00 AM PDT in Seattle.
Harmony Biosciences (HRMY) presents a compelling value opportunity with strong profitability, financial health, and growth—all at an attractive valuation.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will be dismissed, and Lupin will receive a license to launch its generic product no earlier than January 2030 (or July 2030 with pediatric exclusivity), or earlier under certain circumstances.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on Monday, June 9, 2025, at 3:20 p.m., ET
Harmony Biosciences (HRMY) shows strong growth, profitability, and a bullish technical pattern, making it a stock worth watching in the pharmaceuticals sector.
Harmony Biosciences (HRMY) shows strong growth, profitability, and financial health while trading at an attractive valuation, making it a potential pick for value investors.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers strong growth, reasonable valuation, and solid financial health, making it an attractive option for investors seeking affordable growth stocks.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its way to a potential $1B+ opportunity in narcolepsy alone and poised for additional growth from its next-gen pitolisant development programs. The company has demonstrated four consecutive years of profitability and has grown its cash and investments position to over $600M.
Harmony Biosciences Holdings (NASDAQ:HRMY) is a strong affordable growth stock with high growth, solid profitability, and attractive valuation. Learn why it stands out in the pharmaceutical sector.
Uncover the potential of HARMONY BIOSCIENCES HOLDINGS, an undervalued stock. NASDAQ:HRMY maintains a strong financial position and offers an appealing valuation.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results.
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) approved treatments for FXS.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
HARMONY BIOSCIENCES HOLDINGS was identified as a growth stock that isn't overvalued. NASDAQ:HRMY is excelling in various growth indicators while maintaining a solid financial footing.
Based on a technical and fundamental analysis of NASDAQ:HRMY we can say: HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 3:00 p.m. ET.
